What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “single dose administration (DA-5222-R1 one tablet once a day)”In the company’s words, NCT06993181 on ClinicalTrials.gov
- Main trialPhase 1
- “This study is to compare pharmacokinetics and safety profiles of DA-5222 single-administration and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects”In the company’s words, NCT06993181 on ClinicalTrials.gov
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Jul 2025 | Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects | |
| Phase 1Not yet recruiting | Jul 2025 | To Evaluate Effect of Food of DA-5222 in Healthy Adult Subjects | |
| Phase 1Completed | 19 Aug 2025 | Clinical Trial Comparing Single-administration of DA-5222 and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects in Fed State |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026